Interpace Diagnostics Group has entered in to an Agreement with the University of Maryland Medical System (UMMS), which will provide physicians access to ThyGeNEXT™, ThyraMIR®, and PancraGEN® across the entire UMMS network. Physicians can utilize ThyGeNEXT™ and ThyraMIR® to assess indeterminate thyroid nodules and PancraGEN® for indeterminate pancreatic cysts and solid lesions.